Brief: NGM Biopharmaceuticals Inc Expands Oncology Portfolio With First Immuno-Oncology Development Candidate, Ngm707
19/10/2020 12:07
Oct 19 (Reuters) - NGM Biopharmaceuticals Inc NGM.O :
* NGM EXPANDS ONCOLOGY PORTFOLIO WITH FIRST IMMUNO-ONCOLOGY
DEVELOPMENT CANDIDATE, NGM707
* NGM BIOPHARMACEUTICALS - PLANS TO INITIATE FIRST-IN-HUMAN
TESTING OF NGM707 IN MID-2021
Source text for Eikon: ID:nGNX5Zw97m
Further company coverage: NGM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NGM Biopharmaceuticals
See all newsBrief: NGM Biopharmaceuticals Q4 Net Income USD -27.67 Million
Brief: NGM Bio Enters into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group
NGM Biopharmaceuticals Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Ngm Biopharmaceuticals Says It Got Written Notice From Nasdaq Informing It Has Regained Compliance With Nasdaq Listing
Brief: NGM Bio Announces New Clinical Data From Ongoing Trial Of Ngm707 In Advanced Solid Tumors